GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurobiological Technologies Inc (OTCPK:NTII) » Definitions » ROC (Joel Greenblatt) %

Neurobiological Technologies (Neurobiological Technologies) ROC (Joel Greenblatt) % : 1,550.60% (As of Sep. 2009)


View and export this data going back to 1994. Start your Free Trial

What is Neurobiological Technologies ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Neurobiological Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2009 was 1,550.60%.

The historical rank and industry rank for Neurobiological Technologies's ROC (Joel Greenblatt) % or its related term are showing as below:

NTII's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -333.95
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Neurobiological Technologies's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Neurobiological Technologies ROC (Joel Greenblatt) % Historical Data

The historical data trend for Neurobiological Technologies's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurobiological Technologies ROC (Joel Greenblatt) % Chart

Neurobiological Technologies Annual Data
Trend Jun00 Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,178.41 -2,438.72 -2,328.51 -3,404.08 1,349.03

Neurobiological Technologies Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,483.63 -13,559.83 -947.90 66,931.82 1,550.60

Competitive Comparison of Neurobiological Technologies's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Neurobiological Technologies's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurobiological Technologies's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurobiological Technologies's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Neurobiological Technologies's ROC (Joel Greenblatt) % falls into.



Neurobiological Technologies ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2009 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.184 + 0 + 0.305) - (0.82 + 0 + 0.295)
=-0.626

Working Capital(Q: Sep. 2009 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3 + 0 + 0.205) - (0.626 + 0 + 0.029)
=2.55

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Neurobiological Technologies for the quarter that ended in Sep. 2009 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2009 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2009  Q: Sep. 2009
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=20.592/( ( (0.07 + max(-0.626, 0)) + (0.036 + max(2.55, 0)) )/ 2 )
=20.592/( ( 0.07 + 2.586 )/ 2 )
=20.592/1.328
=1,550.60 %

Note: The EBIT data used here is four times the quarterly (Sep. 2009) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurobiological Technologies  (OTCPK:NTII) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Neurobiological Technologies ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurobiological Technologies (Neurobiological Technologies) Business Description

Traded in Other Exchanges
N/A
Address
2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583
Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.
Executives
Ariel Warszawski 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Ryan Heslop 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Management Co Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Fvp Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Value Partners, Lp 10 percent owner 426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940
Fvp Master Fund Lp 10 percent owner FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176
John B Stuppin director
Abraham E Cohen director 500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018
Abraham D Sofaer director HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010
Biotechnology Value Fund L P other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Investments Llc other: Direct Beneficial Owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Neurobiological Technologies (Neurobiological Technologies) Headlines